Back to Agenda
No Marketing of Authorised Products
Session Chair(s)
Richard Bergström, MS
Director General
European Federation of Pharmaceutical Industries and Associations (EFPIA), Belgium
This session will explore the situation when a medicine is approved, but the company has chosen not to put the product on the market for commercial reasons. The panel will explore the practical consequences of international price referencing and (too?) effective off-patent policies, and discuss possible solutions. Session in development
Learning Objective : You will be able to understand the impact of the implementing safety features on medicinal products, understand about the cost impact and the consequences of the strict timing that is foreseen in the Delegated Act of the unique identifier.
Speaker(s)
What Are The Facts?
Frank Wartenberg, PhD
IQVIA, Germany
President Central Europe
The Reality for Generic Companies
Maarten Van Baelen, MBA, MPharm
Medicines for Europe, Belgium
Market Access Director
The Reality for Originator Companies
Richard Bergström, MS
European Federation of Pharmaceutical Industries and Associations (EFPIA), Belgium
Director General
Reactions from a Healthcare System
Stanislav Primozic
Agency for Medicinal Products and Medical Devices, Slovenia
Head, Sector for Pharmacoeconomics, Pharmacovigilance and HTA
Have an account?